Latest Conference Articles

Stephen V. Liu, MD, discusses studies being presented at the 2024 ASCO Annual Meeting that may provide valuable insights into the management of NSCLC.

S. Vincent Rajkumar, MD, discusses highly anticipated abstracts in multiple myeloma that will be presented at the 2024 ASCO Annual Meeting.

Dose reductions of ribociclib plus an NSAI did not decrease the regimen’s efficacy in patients with HR-positive, HER2-negative early breast cancer.

PF-07220060 plus endocrine therapy was tolerable and generated robust response rates in HR-positive, HER2-negative metastatic breast cancer.

Adding denosumab to neoadjuvant nab-paclitaxel did not improve 5-year invasive disease-free survival rates in patients with early-stage breast cancer.

Capivasertib plus fulvestrant improved time to second progression in patients with pretreated HR-positive, HER2-negative advanced breast cancer.

Trastuzumab deruxtecan demonstrated superior long-term survival and response rates vs treatment of physician’s choice in HER2-positive breast cancer.

Datopotamab deruxtecan was associated with lower rates of high-grade TRAEs vs chemotherapy in the phase 3 TROPION-Breast01 trial.

Vepdegestrant plus palbociclib maintained clinical efficacy and safety in patients with pretreated, advanced ER-positive, HER2-negative breast cancer.

Atezolizumab plus chemotherapy did not improve OS vs chemotherapy alone in select patients with early relapsing triple-negative breast cancer.

Olaparib, durvalumab, and fulvestrant produced a 66.7% 24-week PFS rate in patients with endocrine-resistant, ER-positive, HER2-negative breast cancer.

First-line atezolizumab plus sacituzumab govitecan led to responses in PD-L1–positive locally advanced or metastatic triple-negative breast cancer.

No significant difference in time to treatment was found between White and Black patients with bladder cancer, but there remained a difference in treatment outcomes.

Angela Jia, MD, PhD, discusses the current standing of metastasis-directed radiotherapy in prostate cancer and identifies some lingering questions surrounding the modality.

Robert Wang, MD, discusses the presently limited utility of using molecular imagining with quantitative thresholds in distinguishing RCC from oncocytic renal masses.

Darolutamide uptake in metastatic hormone-sensitive prostate cancer has become routine both in doublet and triplet regimens in community urology practices.

TAR-210 was safe and showed promising clinical activity in patients with FGFR-altered high- and intermediate-risk non–muscle-invasive bladder cancer.

Alexander Kutikov, MD, FACS, discusses treatment options for patients with urothelial cancer requiring cystectomy.

Roger Li, MD, discusses the rationale of the phase 3 MoonRISe-1 trial (NCT06319820).

Nadofaragene firadenovec led to durable antitumor activity in BCG-unresponsive NMIBC either with CIS or papillary disease, according to 5-year data from the phase 3 Study CS-003.

UGN-102 with/without TURBT displayed meaningful and similar DFS and DOR rates in newly diagnosed and recurrent low-grade intermediate-risk NMIBC.

Katherine Wang, MD, discusses the role of active surveillance for patients with renal masses and the ongoing MUSIC-KIDNEY project in Michigan.

Joshua J. Meeks, MD, PhD, discusses effectively implementing recent therapeutic advances across the disease continuum of bladder cancer.

18F-DCFPyL PSMA-PET imaging plus multi-parametric MRI improved the detection of clinically significant prostate cancer in low- and high-risk men on active surveillance.

Enzalutamide alone and with leuprolide led to greater rates of undetectable PSA levels vs leuprolide alone in castration-sensitive prostate cancer.

Neal Shore, MD, FACS, discusses the importance of a multidisciplinary team in light of recent developments in urologic oncology.

Apalutamide and ADT elicited a 100% biochemical recurrence-free survival rate at 24 months in high-risk localized prostate cancer following radical prostatectomy.

Outcome improvements with lutetium Lu 177 vipivotide tetraxetan vs ARPI change favored prior treatment with abiraterone vs enzalutamide in mCRPC.

18F-PSMA-1007 PET/CT generated superior locoregional staging results vs multiparametric MRI in patients with prostate cancer.

Concurrent radical cystectomy and extended lymph node dissection did not show benefit vs standard lymph node dissection in muscle invasive urothelial cancer.